1. Medtech Insight
  2. >>Business

Lab Sector Vs. CMS Battle Heats Up As Medicare Agency Moves Forward With 2018 Rates

 
• By David Filmore

Test-makers and labs say the agency is missing large swaths of the market in making its "market-based" lab payment calculation, but CMS stands by its data, and finalized 2018 lab fee schedule rates. Could next steps be in Congress, or the courts?

Medicare, Health Concept

The US Centers for Medicare and Medicaid Services made some tweaks from earlier proposals, but moved ahead with finalizing 2018 payment rates for diagnostic test services that a key lab industry group calls "fundamentally flawed."

Some Firms Happy

While industry groups are crying foul, some individual advanced molecular diagnostic companies that came away with reimbursement increases are expressing satisfaction with CMS' newly finalized rates for 2018.

One...

About 75% of test codes will see payment reductions, while about 10% will see increases, according to the final 2018 Medicare clinical laboratory fee schedule (CLFS) that CMS posted Nov....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.